StockData
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd (TLX) income statement

TLXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as TLPPF
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Feb 20, 2026Score 3/30
$8.96+0.11 (+1.19%)

Close on Nov 18, 2026Market cap $3.04BP/E –Yield –

Telix Pharmaceuticals Ltd income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin
53.1%
Operating margin
3.7%
Net margin
-0.9%
Return on equity, FY2025
–

Financial strength

Current ratio
2.01
Debt to equity
–
Debt to assets
37.9%
Cash to current liabilities
103.9%

Valuation

P/E ratio
–
Price to sales
3.78
Price to book
–
Dividend yield
–

See a number that looks wrong?